Cariprazine
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Jun 26, 2020 → Dec 10, 2021
NCT ID
NCT04382885About Cariprazine
Cariprazine is a phase 1 stage product being developed by AbbVie for Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04382885. Target conditions include Autism Spectrum Disorder.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04382885 | Phase 1 | Completed |
Competing Products
20 competing products in Autism Spectrum Disorder